Th1 and Th2 lymphocytes in autoimmune disease

Critical Reviews in Immunology

Volumn 25, Issue 2, 2005, Pages 75-102

  Crane, Isabel J ^a   Forrester, John V ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Experimental autoimmune encephalomyelitis; Experimental autoimmune uveoretinitis; Insulin dependent diabetes mellitus; Multiple sclerosis

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; EOTAXIN; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL POLARITY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; UVEITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELL POLARITY; HUMANS; INFLAMMATION; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS;

EID: 21344467014     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v25.i2.10     Document Type: Review

References (259)

1. Chtanova T, Mackay CR. T cell effector subsets: extending the Th1/Th2 paradigm. Adv Immunol 2001; 78:233-266.
2. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-66.
3. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, OGarra A. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 1996; 183:901-913.
4. Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 1997; 186:299-306.
5. Mosmann TR, Chenvinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357.
6. + T cell populations. Int Immunol 1999; 11:617-621.
7. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
8. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8:275-283.
9. Kamogawa Y, Minasi L-AE, Carding SR, Bottomly K, Flavell RA. The relationship of IL-4 and IFN-γ-producing T cells studied by lineage ablation of IL-4 producing cells. Cell 1993; 75:985-995.
10. Perussia B, Loza MJ. Linear '2-0-1' lymphocyte development: hypotheses on cellular bases for immunity. Trends Immunol 2003; 24:235-241.
11. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-795.
12. Kopf M, LeGros G, Coyle AJ, Kosco Vilbois M, Brombacher F. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immun Rev 1995; 148:45-69.
13. Finkelman FD, Katona IM, Urban JF, Holmes J, Ohara J, Tung AS, Sample JV, Paul WE. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988; 141:2335-2341.
14. Jose PJ, Griffithsjohnson DA, Coffins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ. Eotaxin - a potent eosinophil chemo-attractant cytokine detected in a guinea-pig model of allergic airways inflammation. J Exp Med 1994; 179:881-887.
15. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000; 6:20-27.
16. Wills-Karp M, Luyimbazi J, Xu XY, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2261.
17. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
18. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003; 33:1767-1775.
19. Mazzoni A, Segal DM. Controlling the Toll road to dendritic cell polarization. J Leukocyte Biol 2004; 75:721-730.
20. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O, Moser M. CD4(+) CD25(+) regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003; 198:259-266.
21. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206-1212.
22. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16:1391-1401.
23. Nicholson LB, Wraith DC. T-cell receptor degeneracy: the dog that did not bark-adaptation of the self-reactive T-cell response to limit autoimmune disease. Mol Immunol 2004; 40:997-1002.
24. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 2004; 117:515-526.
25. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993; 14: 335-338.
26. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin-12 acts directly on CD4+ T-cells to enhance priming for interferon-gamma production and diminishes interleukin-4 inhibition of such priming. Proc Natl Acad Sci U S A 1993; 90:10188-10192.
27. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S. Natural-killer-cell stimulatory factor (Interleukin-12 [IL-12]) induces T-helper Type-1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199-1204.
28. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998; 8:383-390.
29. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, Malefyt RD, Rennick D, Kastelein RA. IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779-790.
30. Oppmann B, Lesley R, Blom B, Timans JC, Xu YM, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu MR, Gorman D, Wagner J, Zurawski S, Liu YJ, Abrams JS, Moore KW, Rennick D, Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-725.
31. Magram J, Connaughton SE, Warner RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996; 4:471-481.
32. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996; 382:174-177.
33. Langrish CL, McKenzie BS, Wilson NJ, Malefyt RD, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202:96-105.
34. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-Bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170:4886-4890.
35. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14:1693-1711.
36. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000; 10:542-550.
37. Rao A, Avni O. Molecular aspects of T-cell differentiation. Br Med Bull 2000; 56:969-984.
38. Sinigaglia F, D'Ambrosio D, Rogge L. Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol 1999; 23:657-663.
39. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating TH1 immune responses. Ann Rev Immunol 2003; 21:713-758.
40. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni MP, Rugiu FS, Decarli M, Ricci M, Romagnani S. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148:2142-2147.
41. Fitch FW, Mckisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T-lyrnphocyte subsets. Ann Rev Immunol 1993; 11:29-48.
42. Sher A, Coffman RL. Regulation of immunity to parasites by T-cells and T-cell derived cytokines. Ann Rev Immunol 1992; 10:385-409.
43. Parronchi P, Decarli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, Macchia D, Maggi E, Delprete G, Romagnani S. IL-4 and IFN (Alpha and Gamma) exert opposite regulatory effects on the development of cytolytic potential by TH1 or TH2 human T-cell clones. J Immunol 1992; 149:2977-2983.
44. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004; 431:527-532.
45. Zhang Y, Apilado R, Coleman J, Ben Sasson S, Tsang S, Hu-Li J, Paul WE, Huang H. Interferon (gamma) stabilizes the T helper cell type 1 phenotype. J Exp Med 2001; 194:165-172.
46. Guler ML, Gorham JD, Hsieh CS, Mackey AJ, Steen RG, Dietrich WF, Murphy KM. Genetic susceptibility to Leishmania: IL-12 responsiveness in T(H)1 cell development. Science 1996; 271:984-987.
47. Sun B, Rizzo LV, Sun S-H, Chan C-C, Wiggert B, Wilder RL, Caspi RR. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T Helper-1-like or a T Helper-2-like response. J Immunol 1997; 159: 1004-1011.
48. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann Rev Immunol 2000; 18: 217-243.
49. Roffins BJ. Chemokines. Blood 1997; 90:909-928.
50. Janeway CA, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002; 20:197-216.
51. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:2887-2894.
52. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase upregulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003; 544:129-132.
53. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298:1025-1029.
54. Zou WP, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, Curiel TJ. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165:4388-4396.
55. Sato N, Kuziel WA, Melby PC, Reddick RL, Kostecki V, Zhao WG, Maeda N, Ahuja SK, Ahuja SS. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2- deficient mice. J Immunol 1999; 163:5519-5525.
56. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2:102-107.
57. Luksch CR, Winqvist O, Ozaki ME, Karlsson L, Jackson MR, Peterson PA, Webb SR. Intercellular adhesion molecule-1 inhibits interleukin 4 production by naive T cells. Proc Natl Acad Sci U S A 1999; 96: 3023-3028.
58. Salomon B, Bluestone JA. Cutting edge: LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol 1998; 161:5138-5142.
59. De Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 2005; 26:289-307.
60. Schweitzer AN, Borriello F, Wong RCK, Abbas AK, Sharpe AH. Role of costimulators in T cell differentiation-studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol 1997; 158:2713-2722.
61. Burr JS, Kimzey SL, Randolph DR, Green JM. CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T-Helper cell differentiation after inhaled allergen. Am J Resp Cell Mol Biol 2001; 24:563-568.
62. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997; 158:658-665.
63. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, Noda T, Sugamura K. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000; 191:365-374.
64. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell Type 2 differentiation in experimental Leishmaniasis. J Exp Med 2000; 191:375-380.
65. Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 Cells. J Exp Med 2000; 191:201-206.
66. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways - application to autoimmune disease therapy. Cell 1995; 80:707-718.
67. Ranger AM, Das MP, Kuchroo VK, Glimcher LH. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 1996; 8:1549-1560.
68. Nakajima A, Watanabe N, Yoshino S, Yagita H, Okumura K, Azuma M. Requirement of CD28-CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells. Int Immunol 1997; 9:637-644.
69. Subramanian G, Kazura JW, Pearlman E, Jia XL, Malhotra I, King CL. B7-2 requirement for helminth-induced granuloma formation and CD4 type 2 T helper cell cytokine expression. J Immunol 1997; 158:5914-5920.
70. Dong HD, Zhu GF, Tamada K, Chen LP. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-1369.
71. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-266.
72. Ling V, Wu PW, Finnerty HF, Bean KM, Spaulding V, Fouser LA, Leonard JP, Hunter SE, Zollner R, Thomas JL, Miyashiro JS, Jacobs KA, Collins M. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol 2000; 164:1653-1657.
73. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai TN, Duncan G, Elliott GS, Hui A, Mccabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402:827-832.
74. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong HD, Sica GL, Zhu GF, Tamada K, Chen LP. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2:269-274.
75. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, Wakeham A, Itie A, Chung S, Da Costa J, Arya S, Horan T, Campbell P, Gaida K, Ohashi PS, Watts TH, Yoshinaga SK, Bray MR, Jordana M, Mak TW. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4: 899-906.
76. Shortman K, Wu L. Parentage and heritage of dendritic cells. Blood 2001; 97:3325.
77. Maldonado-Lopez R, Maliszewski C, Urbain J, Moser M. Cytokines regulate the capacity of CD8 alpha(+) and CD8 alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 2001; 167:4345-4350.
78. Pulendran B, Smith JL, Caspary G, Brasel K, Petit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Nad Acad Sci U S A 1999; 96: 1036-1041.
79. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-592.
80. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, Malefyt RD, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183-1186.
81. Smith AL, St Groth BF. Antigen-pulsed CD8 alpha(+) dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 1999; 189:593-598.
82. Constant SL, Bottomly K. Induction of TH1 and TH2 CD4+ T cell responses: the alternative approaches. Ann Rev Immunol 1997; 15:297-322.
83. Tao X, Constant S, Jorritsma P, Bottomly K. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4(+) T cell differentiation. J Immunol 1997; 159:5956-5963.
84. Grakoui A, Donermeyer DL, Kanagawa O, Murphy KM, Allen PM. TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. J Immunol 1999; 162:1923-1930.
85. Singh RAK, Zang YCQ, Shrivastava A, Hong J, Wang GT, Li SF, Tejada-Simon MV, Kozovska M, Rivera VM, Zhang JWZ. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J Immunol 1999; 163:6393-6402.
86. Singh RAK, Zhang JWZ. Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol 2004; 173:7299-7307.
87. Nicholson LB, Anderson AC, Kuchroo VK. Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. Int Immunol 2000; 12: 205-213.
88. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/ Th2-mediated responses. Immunol Today 1998; 19: 568-574.
89. Foxman EF, Zhang MF, Hurst SD, Muchamuel T, Shen DF, Wawrousek EF, Chan CC, Gery I. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol 2002; 168: 2483-2492.
90. Schrum S, Probst P, Fleischer B, Zipfel PF. Synthesis of the CC-chemokines MIP-1α, MIP-1β and RANTES is associated with a type 1 immune response. J Immunol 1996; 157:3598-3604.
91. Bradley LM, Asensio VC, Schioetz L-K, Harbertson J, Krahl T, Patstone G, Woolf N, Campbell IL, Sarvetnick N. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162: 2511-2520.
92. Zhang SM, Lukacs NW, Lawless VA, Kunkel SL, Kaplan MH. Cutting edge: differential expression of chemokines in Th1 and Th2 cells is dependent on Stato but not Stat4. J Immunol 2000; 165:10-14.
93. Song HK, Noorchashm H, Lin TH, Moore DJ, Greeley SA, Caton AJ, Naji A. Specialized CC-chemokine secretion by Th1 cells in destructive autoimmune myocarditis. J Autoimmunol 2003; 21:295-303.
94. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol 1997; 15: 675-705.
95. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann Rev Immunol 2004; 22:891-928.
96. Chensue SW. Molecular machinations: chemokine signals in host-pathogen interactions. Clin Microbiol Rev 2001; 14:821-835.
97. + T cell survival. J Immunol 2004; 172:6065-6073.
98. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, Tonegawa S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodefiaent hosts rather than protect them from the disease. J Exp Med 1997; 186:307-312.
99. Bridoux F, Badou A, Saoudi A, Bernard I, Druet E, Pasquier R, Druet P, Pelletier L. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J Exp Med 1997; 185:1769-1775.
100. Sakaguchi S. Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004; 22:531-562.
101. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004; 16:89-97.
102. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3:223-232.
103. Brod SA, Benjamin D, Hafler DA. Restricted T-cell expression of IL-2/IFN-gamma messenger-RNA in human inflammatory disease. J Immunol 1991; 147: 810-815.
104. Decarli M, Delios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, Delprete G. Cytolytic T-cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates Graves ophthalmopathy. J Clin Endocrinol Metab 1993; 77: 1120-1124.
105. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Nad Acad Sci U S A 1994; 91:8562-8566.
106. Romagnani S. T-cell subsets (Th1,Th2) and cytokines in autoimmunity. In: Rose NR, Mackay IR, editors. The autoimmune diseases. New York: Academic Press; 1998. p. 163-192.
107. Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990; 249:1433-1436.
108. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway Jr CA. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177:57-68.
109. Bergman B, Haskins K. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 1994; 43:197-203.
110. Caspi RR, Silver PB, Chan C-C, Sun B, Agarwal RK, Wells J, Oddo S, Fujino Y, Najafian F, Wilder RL. Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol 1996; 157:2668-2675.
111. Karpus WJ, Ransohoff RM. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol 1998; 161:2667-2671.
112. Karpus WJ, Lukacs NW, McRae BL, Stricter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155:5003-5010.
113. Youssef S, Wildbaum G, Maor G, Lanir N, GourLavie A, Grabie N, Karin N. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161:3870-3879.
114. Kennedy KJ, Stricter RM, Kunkel SL, Lukacs NW, Karpus WJ. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92:98-108.
115. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999; 96:6873-6878.
116. Sorensen TL,Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin SX, Rottman J, Sellebjerg F, Stricter RM, Frederiksen JL, Ransohoff RM. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807-815.
117. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746-754.
118. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune-disease. J Exp Med 1994; 180: 1961-1966.
119. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D, Veromaa T, Waisman A, Gaur A, Conlon P, Ling N, Fairchild PJ, Wraith DC, O'Garra A, Fathman CG, Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379:343-346.
120. Rizzo LV, Xu H, Chan C-C, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 1998; 10:807-814.
121. Pennline KJ, Roquegaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-175.
122. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL. Interleukin-4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99.
123. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, Chakrabarti S, Delovitch TL. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159: 4686-4692.
124. Mueller R, Krahl T, SarvetnickN. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184:1093-1099.
125. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158: 2414-2424.
126. Gallichan WS, Balasa B, Davies JD, Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696-1703.
127. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against Interleukin-12. J Exp Med 1995; 181:381-386.
128. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Ann Rev Immunol 2002; 20:101-123.
129. Fowell D, Mason D. Evidence that the T-cell repertoire of normal rats contains cells with the potential to cause diabetes - characterization of the CD4+ T-cell subset that inhibits this autoimmune potential. J Exp Med 1993; 177:627-636.
130. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple-sclerosis with gamma-interferon - exacerbations associated with activation of the immune system. Neurology 1987; 37:1097-1102.
131. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192:123-128.
132. Ferber IA, Brocke S, TaylorEdwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156:5-7.
133. Duong TT, Stlouis J, Gilbert JJ, Finkelman FD, Strejan GH. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal-antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the Sjl/J mouse. J Neuroimmunol 1992; 36:105-115.
134. Billiau A, Heremans H, Vanderkerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H. Enhancement of allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988; 140:1506-1510.
135. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, Martino G. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001; 167:1821-1829.
136. Krakowski M, Owens T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26:1641-1646.
137. Tran EH, Prince EN, Owens T. IFN-γ shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000; 164:2759-2768.
138. Liversidge J, Forrester JV. Experimental autoimmune uveitis (EAU): immunophenotypic analysis of inflammatory cells in chorio retinal lesions. Curr Eye Res 1988; 7:1231-1241.
139. Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, Sedgwick JD. Inhibition of tumour necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996; 26:1018-1025.
140. Caspi RR, Roberge FG, Chan C, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988; 140: 1490-1495.
141. Caspi RR, Chan C-C, Wiggert B, Chader GJ. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr Eye Res 1990; 9 Suppl: 169-174.
142. Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG. Experimental autoimmune uveoretinitis: a model system for immunointervention: a review. Curr Eye Res 1992; 11 Suppl:33-40.
143. Prendergast RA, Iliff CE, Coskuncan NM, Caspi RR, Sartani G, Tarrant TK, Lutty GA, McLeod DS. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 1998; 39:754-762.
144. Silver PB, Chan C-C, Wiggert B, Caspi RR. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999; 40: 2898-2905.
145. Egwuagu CE, Sztein J, Mahdi RM, Li W, Chao-Chan C, Smith JA, Charukamnoetkanok P, Chepelinsky AB. IFN-γ increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J Immunol 1999; 162:510-517.
146. Caspi RR, Chan C-C, Grubbs BG, Silver PB, Wiggert B, Parsa CF, Bahmanyar S, Billiau A, Heremans H. Endogenous systemic IFN-γ has a protective role against ocular autoimmunity in mice. J Immunol 1994; 152:890-899.
147. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan C-C, Wiggert B, Caspi RR. IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997; 158:5997-6005.
148. Khoruts A, Miller SD, Jenkins MK. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 1995; 155:5011-5017.
149. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, Raine CS, Hauser SL. Late complications of immune deviation therapy in a non-human primate. Science 1996; 274:2054-2057.
150. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170-175.
151. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8:681-694.
152. Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, Lassmann H, Linington C. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999; 163:40-49.
153. Lassmann H. Pathology of multiple sclerosis. In: Compston A, editor. McAlpine's Multiple Sclerosis. London: Churchill Livingstone; 1998. p. 323-358.
154. Takeuchi M, Yokoi H, Tsukahara R, Sakai J, Usui M. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis. Jpn J Ophthalmol 2001; 45: 463-469.
155. Keino H, Takeuchi M, Suzuki J, Kojo S, Sakai J, Nishioka K, Sumida T, Usui M. Identification of Th2-type suppressor T cells among in vivo expanded ocular T cells in mice with experimental autoimmune uveoretinitis. Clin Exp Immunol 2001; 124:1-8.
156. Saoudi A, Kuhn J, Huygen K, de Kozak Y, Velu T, Goldman M, Druet P, Bellon B. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol 1993; 23:3096-3103.
157. Yotsukura J, Huang H, Singh AK, Shichi H. Regulatory cells generated by testicular tolerization to retinal S-antigen: possible involvement of IL-4, IL-10, and TGF-beta in the suppression of experimental autoimmune uveoretinitis. Cell Immunol 1997; 182: 89-98.
158. de Kozak Y, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002; 130: 212-223.
159. Kim SJ, Zhang M, Vistica BP, Chan CC, Shen DF, Wawrousek EF, Gery I. Induction of ocular inflammation by T-helper lymphocytes type 2. Invest Ophthalmol Vis Sci 2002; 43:758-765.
160. Atkinson MA, Maclaren NK. Mechanisms of disease - the pathogenesis of
161. Castano L, Eisenbarth G S. Type-I diabetes - a chronic autoimmune-disease of human, mouse, and rat. Ann Rev Immunol 1990; 8:647-679.
162. + T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9:872-883.
163. O'Reilly LA, Hutchings PR, Crocker PR, Simpson E, Lund T, Kioussis D, Takei F, Baird J, Cooke A. Characterization of pancreatic-islet cell infiltrates in NOD mice - effect of cell transfer and transgene expression. Eur J Immunol 1991; 21:1171-1180.
164. Katz JD, Benoist C, Mathis D. T-helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185-1188.
165. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T-cell from genesis through pathogenesis. Cell 1993; 74:1089-1100.
166. Kurrer MO, Pakala SV, Hanson HL, Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A 1997; 94:213-218.
167. Haskins K, Wegmann D. Diabetogenic T-cell clones. Diabetes 1996; 45:1299-1305.
168. Campbell IL, Kay TWH, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87:739-742.
169. Sarvetnick N, Shizuru J, Liggitt D, Martin L, Mcintyre B, Gregory A, Parslow T, Stewart T. Loss of pancreatic-islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990; 346:844-847.
170. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin-12 administration induces T-helper Type-1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181:817-821.
171. Rothe H, Ohara RM, Martin S, Kolb H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)(2). Diabetologia 1997; 40:641-646.
172. Nitta Y, Kawamoto S, Tashiro F, Aihara H, Yoshimoto T, Nariuchi H, Tabayashi K, Miyazaki J. IL-12 plays a pathologic role at the inflammatory loci in the development of diabetes in NOD mice. J Autoimmunol 2001; 16:97-104.
173. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85:291-297.
174. Poulin M, Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T cell clones from a TCR transgenic mouse. J Immunol 2000; 164: 3072-3078.
175. Tisch R, Wang B, Atkinson MA, Serreze DV, Friedline R. Aglutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 166: 6925-6936.
176. Darabi K, Karulin AY, Boehm BO, Hofstetter HH, Fabry Z, LaManna JC, Chavez JC, Tary-Lehmann M, Lehmann PV. The third signal in T cell-mediated autoimmune disease? J Immunol 2004; 173:92-99.
177. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, Karulin A, Lehmann PV. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol 2000; 164:5771-5781.
178. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186:1623-1631.
179. Segal BM, Chang JT, Shevach EM. CPG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000; 164:5683-5688.
180. Fearon DT, Locksley RM. Elements of immunity-the instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-54.
181. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, Trezza RP, Heinzel FP, Forsthuber T, Lehmann PV. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999; 162:3942-3949.
182. Forsthuber T, Yip HC, Lehmann PV. Induction of T(H)1 and T(H)2 immunity in neonatal mice. Science 1996; 271:1728-1730.
183. Jakob T, Walker PS, Krieg AM, von Stebut E, Udey MC, Vogel JC. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999; 118:457-461.
184. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879-2883.
185. Takeda K, Kaisho T, Akira S. Toll-like receptors. Ann Rev Immunol 2003; 21:335-376.
186. Hou W, Wu Y, Sun S, Shi M, Sun Y, Yang C, Pei G, Gu Y, Zhong C, Sun B. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 2003; 170:1728-1736.
187. Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 2002; 169:117-125.
188. Shive CL, Hofstetter H, Arredondo L, Shaw C, Forsthuber TG. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur J Immunol 2000; 30:2422-2431.
189. Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, Littman DR, Rollins BJ, Zweerink H, Rot A, von Andrian UH. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissue. J Exp Med 2001; 194:1361-1373.
190. Su SB, Silver PB, Zhang MF, Chan CC, Caspi RR. Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J Immunol 2001; 167:250-256.
191. Agarwal RK, Sun SH, Su SB, Chan CC, Caspi RR. Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity. J Neuroimmunol 2002; 129:133-140.
192. Su SB, Silver PB, Wang P, Chan CC, Caspi RR. Dissociating the enhancing and inhibitory effects of pertussis toxin on autoimmune disease. J Immunol 2003; 171:2314-2319.
193. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Requirements for passage of T lymphocytes across non-inflamed retinal microvessels. J Neuroimmunol 2003; 142:47-57.
194. Biernacki K, Prat A, Blain M, Antel JP. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. J Neuropathol Exp Neurol 2004; 63:223-232.
195. Hofstetter HH, Sewell DL, Liu F, Sandor M, Forsthuber T, Lehmann PV, Fabry Z. Autoreactive T cells promote post-traumatic healing in the central nervous system. J Neuroimmunol 2003; 134:25-34.
196. Hanyecz A, Berlo SE, Szanto S, Broeren CPM, Mikecz K, Glant TT. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthritis Rheum 2004; 50:1665-1676.
197. + myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-γ in autoimmune disease models. Trends Immunol 2001; 22:367-371.
198. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Schols D, Wolf-Peeters C, Billiau A. Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1(+) myeloid cells. J Immunol 1999; 163:3503-3510.
199. Vermeire K, Heremans H, Vandeputte M, Huang S, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997; 158:5507-5513.
200. Zhang GX, Xiao BG, Bai XF, Van der Meide PH, Orn A, Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999; 162:3775-3781.
201. Balasa B, Deng CS, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia gravis in mice. J Exp Med 1997; 186: 385-391.
202. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol 1996; 62:61-130.
203. Willenborg DO, Fordham S, Bernard CCA, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996;157:3223-3227.
204. Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol 1999; 163:5278-5286.
205. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 1998; 161:122-127.
206. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187:537-546.
207. Tarrant TK, Silver PB, Wahlsten JL, Rizzo LV, Chan CC, Wiggert B, Caspi RR. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med 1999; 189:219-230.
208. Gran B, Zhang GX, Yu S, Li JF, Chen XH, Ventura ES, Kamoun M, Rostami A. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169:7104-7110.
209. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24:242-248.
210. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-774.
211. Olivares-Villagomez D, Wensky AK, Wang YJ, Lafaille JJ. Repertoire requirements of CD4(+) T cells that prevent spontaneous autoimmune encephalomyelitis. J Immunol 2000; 164:5499-5507.
212. Gonzalez A, Andre-Schmutz I, Carnaud C, Mathis D, Benoist C. Damage control, rather than unresponsiveness, effected by protective DX5+T cells in autoimmune diabetes. Nat Immunol 2001; 2:1117-1125.
213. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25(+) CD4(+) T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001; 166:3008-3018.
214. Stephens LA,Mason D. CD25 is a marker for CD4(+) thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25(+) and CD25(-) subpopulations. J Immunol 2000; 165:3105-3110.
215. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003; 197:451-460.
216. Piccirillo CA, Shevach EM. Naturally-occurring CD4(+)CD25(+) immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16:81-88.
217. Nacy CA, Meltzer MS. T-cell-mediated activation of macrophages. Curr Opin Immunol 1991; 3: 330-335.
218. Liew FY. Induction and regulation of CD4+ T cell subsets. Ciba Found Symp 1994; 187:170-175.
219. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996; 184:741-746.
220. Agarwal RK, Chan CC, Wiggert B, Caspi RR. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. J Immunol 1999; 162: 2648-2654.
221. Xu H, Manivannan A, Jiang H-R, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Recruitment of IFNγ-producing (Th1-like) cells into the inflamed retina in vivo is preferentially regulated by PSGL-1: P/E selectin interactions. J Immunol 2004; 172: 3215-3224.
222. Kim SJ, Zhang M, Vistica BP, Chan CC, Shen DF, Wawrousek EF, Gery I. Induction of ocular inflammation by T-helper lymphocytes type 2. Invest Ophthalmol Vis Sci 2002; 43:758-765.
223. Hommel M, Kyewski B. Dynamic changes during the immune response in T cell-antigen- presenting cell clusters isolated from lymph nodes. J Exp Med 2003; 197:269-280.
224. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67:1033-1036.
225. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-314.
226. Katakai T, Hara T, Sugai M, Gonda H, Nambu Y, Matsuda E, Agata Y, Shimizu A. Chemokine-independent preference for T-helper-1 cells in transendothelial migration. J Biol Chem 2002; 277: 50948-50958.
227. Katakai T, Mori KJ, Masuda T, Shimizu A. Selective accumulation of type 1 effector cells expressing P-selectin ligand and/or alpha(4)beta(7)-integrin at the lesions of autoimmune gastritis. Int Immunol 2002; 14:167-175.
228. Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997; 385:81-83.
229. Borges E, Pendl G, Eytner R, Steegmaier M, Zollner O, Vestweber D. The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J Biol Chem 1997; 272: 28786-28792.
230. Smithson G, Rogers CE, Smith PL, Scheidegger EP, Petryniak B, Myers JT, Kim DS, Homeister JW, Lowe JB. Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J Exp Med 2001; 194:601-614.
231. van Wely CA, Blanchard AD, Britten CJ. Differential expression of alpha3 fucosyltransferases in Th1 and Th2 cells correlates with their ability to bind P-selectin. Biochem Biophys Res Commun 1998; 247:307-311.
232. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389:978-981.
233. Clissi B, D'Ambrosio D, Geginat J, Colantonio L, Morrot A, Freshney NW, Downward J, Sinigaglia F, Pardi R. Chemokines fail to up-regulate beta 1 integrin-dependent adhesion in human Th2 T lymphocytes. J Immunol 2000; 164:3292-3300.
234. D'Ambrosio D, Iellem A, Colantonio L, Clissi B, Pardi R, Sinigaglia F. Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol Today 2000; 21:183-186.
235. Ostermann G, Weber KSC, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol 2002; 3:151-158.
236. Raab M, Daxecker H, Markovic S, Karimi A, Griesmacher A, Mueller MM. Variation of adhesion molecule expression on human umbilical vein endothelial cells upon multiple cytokine application. Clin Chim Acta 2002; 321:11-16.
237. Li Q, Sun B, Matteson DM, O'Brien TP, Chan CC. Cytokines and apoptotic molecules in experimental melanin-protein induced uveitis (EMIU) and experimental autoimmune uveoretinitis (EAU). Autoimmunity 1999; 30:171-182.
238. Tang HW, Sharp GC, Peterson KP, Braley-Mullen H. IFN-gamma-deficient mice develop severe granulomatous experimental autoimmune thyroiditis with eosinophil infiltration in thyroids. J Immunol 1998; 160:5105-5112.
239. Gershon RK, Kondo K. Infectious immunological tolerance. Immunol 1970; 18:723-735.
240. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunological self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chains (Cd25)-breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-1164.
241. Ruiz PJ, Garren H, Hirschberg DL, Langer-Gould AM, Levite M, Karpuj MV, Southwood S, Sette A, Conlon P, Steinman L. Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. J Exp Med 1999; 189: 1275-1283.
242. Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun 2001; 16:115-123.
243. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002; 196:255-260.
244. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-463.
245. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4(+) CD25(+) regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-979.
246. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4(+) CD25(+) regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004; 199:1285-1291.
247. Kukreja A, Cost G, Marker J, Zhang CH, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140.
248. Wraith DC, Nicolson KS, Whitley NT. Regulatory CD4(+) T cells and the control of autoimmune disease. Curr Opin Immunol 2004; 16:695-701.
249. Chen YH, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T-cell clones induced by oral tolerance-suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-1240.
250. Han HS, Jun HS, Utsugi T, Yoon JW. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996; 9:331-339.
251. Zekzer D, Wong FS, Wen L, Altieri M, Gurlo T, vonGrafenstein H, Sherwin RS. Inhibition of diabetes by an insulin-reactive CD4 T-cell done in the nonobese diabetic mouse. Diabetes 1997; 46:1124-1132.
252. Chen C, Lee WH, Yun P, Snow P, Liu CP. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol 2003; 171:733-744.
253. Flaishon L, Topilski I, Shoseyov D, Hershkoviz R, Fireman E, Levo Y, Marmor S, Shachar I. Cutting edge: anti-inflammatory properties of low levels of IFN-gamma. J Immunol 2002; 168:3707-3711.
254. Moore KW, OGarra A, Malefyt RD, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11:165-190.
255. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999; 189:1005-1010.
256. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998; 161:3299-3306.
257. Wogensen L, Lee MS, Sarvetnick N. Production of Interleukin-10 by islet cells accelerates immune-mediated destruction of beta-cells in nonobese diabetic mice. J Exp Med 1994; 179:1379-1384.
258. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J, Ii S, Kudo E, Iwahana H, Hayashi Y, Sano T, Itakura M. Transgenic expression of IL-10 in pancreatic-islet A-cells accelerates autoimmune insulitis and diabetes in nonobese diabetic mice. Int Immunol 1994; 6:1927-1936.
259. Cannella B, Gao YL, Brosnan C, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996; 45:735-746.